The American Diabetes Association 69th Scientific Sessions took place on June 5-9 in New Orleans, Louisiana.

It was encouraging for diabetes treatment in general that new analyses from the ACCORD and VADT cardiovascular outcomes trials suggest that more aggressive treatment in certain subgroups of patients could have a cardiovascular benefit, despite negative findings presented last year for each study as a whole.

On the whole, there was little groundbreaking data at this year’s ADA, but several drugs reported their first significant A1C data. These included GLP-1 agonists LY2189265 (LLY) and Syncria (GSK), as well as DPP-IV inhibitors Ondero (Boehringer) and PF-00734200 (PFE). It was interesting to see details to better understand competitive features and potential pitfalls, though none of the drugs emerged as a clear leader in its class. Other new data was also presented for remogliflozin (GSK), a member of the emerging SGLT2 inhibitor class that is generating growing interest, and PPAR alpha/gamma agonist aleglitazar.

While there were a number of drugs with novel mechanisms of action - such as the enzyme 11beta-HSD1, the FRX receptor, and the cytokine IL-1 beta - data was early stage, and efficacy appeared relatively modest, though it was interesting that Bayhill’s pro-insulin vaccine (BHT-3021) had signals suggesting it may be able to stabilize the A1C decline due to autoimmunity in Type 1 diabetes.

A number of other drugs are also discussed, as well as summaries for some drug classes. Please also see our Pre-ADA Report for additional background information.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.